Document is current

Any future updates will be listed below

Long-Term Cost-Effectiveness Analysis of Once-Weekly Semaglutide versus Dulaglutide in Patients with Type 2 Diabetes with Inadequate Glycemic Control in China

Crossref DOI link: https://doi.org/10.1007/s13300-022-01301-4

Published Online: 2022-08-08

Published Print: 2022-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark